Hyperosmolar Potassium (K(+)) Treatment Suppresses Osteoarthritic Chondrocyte Catabolic and Inflammatory Protein Production in a 3-Dimensional In Vitro Model

高渗钾(K(+))治疗可抑制三维体外模型中骨关节炎软骨细胞的分解代谢和炎症蛋白的产生

阅读:1

Abstract

OBJECTIVE: The main goal of this study was to provide a proof-of-concept demonstrating that hyperosmolar K(+) solutions can limit production of catabolic and inflammatory mediators in human osteoarthritic chondrocytes (OACs). METHODS: A 3-dimensional in vitro model with poly(ethylene glycol) diacrylate (PEGDA) hydrogels was used. Catabolic and pro-inflammatory protein production from encapsulated OACs was assessed following culture for 1 or 7 days in the presence or absence of 80 mM K(+) gluconate, 80 mM sodium (Na(+)) gluconate, or 160 mM sucrose, each added to culture media (final osmolarity ~490 mOsm). RESULTS: Relative to untreated controls, OACs treated with hyperosmolar (80 mM Na(+) gluconate or 160 mM sucrose) solutions produced lower levels of catabolic and inflammatory mediators in a marker- and time-dependent manner (i.e., MMP-9 after 1 day; MCP-1 after 7 days ( P ≤ 0.015)). In contrast, OAC treatment with 80 mM K(+) gluconate reduced catabolic and inflammatory mediators to a greater extent (both the number of markers and degree of suppression) relative to untreated, Na(+) gluconate, or sucrose controls (i.e., MMP-3, -9, -13, TIMP-1, MCP-1, and IL-8 after 1 day; MMP-1, -3, -9, -13, TIMP-1, MCP-1, and IL-8 after 7 days ( P ≤ 0.029). CONCLUSIONS: Hyperosmolar K(+) solutions are capable of attenuating protein production of catabolic and inflammatory OA markers, providing the proof-of-concept needed for further development of a K(+)-based intra-articular injection for OA treatment. Moreover, K(+) performed significantly better than Na(+)- or sucrose-based solutions, supporting the application of K(+) toward improving irrigation solutions for joint surgery.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。